NCT04004429View on ClinicalTrials.gov

A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

105

Participants

Timeline

Start Date

August 26, 2019

Primary Completion Date

November 16, 2021

Study Completion Date

November 16, 2021

Conditions

Rheumatoid Arthritis

Interventions

DRUG

50 mg AP1189

50 mg AP1189 powder in bottle

DRUG

AP1189

100 mg AP1189 powder in bottle

DRUG

Placebo

Placebo powder in bottle

Trial Locations (2)

8200

Aarhus Universitetshospital, Aarhus

0370

Diakonhjemmet Sykehus, Oslo

All Listed Sponsors

lead

SynAct Pharma Aps

INDUSTRY

NCT04004429 - A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease | Biotech Hunter | Biotech Hunter